Shots:
- The P-III (SAFFRON) trial assessed Orpathys (300mg; BID) + Tagrisso (80mg; QD) vs doublet Pt-based CT in 338 pts with EGFRm, LA/M NSCLC with MET overexpression or amplification whose disease progressed following 1 or 2L treatment with Tagrisso
- The trial showed a statistically significant & clinically meaningful improvement in both PFS & OS, with a favorable safety profile; data to be presented at an upcoming medical meeting & shared with global regulatory authorities
- In China, Orpathys + Tagrisso is approved for EGFRm NSCLC with MET amplification after EGFR-TKI progression, based on P-III (SACHI) trial data
Ref: Businesswire | Image: HUTCHMED | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
